BioMarin Pharmaceutical | BMRN - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Bayer EUR -1.16B 735M 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
Incyte USD 389.94M 92.37M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09